RUNX3 and lymphoid leukemia: Indeed, genetic evidence implicates almost every one of its components (as inferred from the fly counterparts) in cancer: AML1 and RUNX3 are tumour suppressors whose inactivation is prevalent in myeloid and lymphocytic leukemias (Mangan and Speck, 2011), and in a wide range of solid tumors including colorectal cancer (Chuang et al., 2013), respectively.